Motomi Enomoto-Iwamoto Selected Research

Osteochondroma (Osteocartilaginous Exostosis)

12/2021	Osteochondroma Pathogenesis: Mouse Models and Mechanistic Insights into Interactions with Retinoid Signaling.
4/2020	Understanding the Action of RARγ Agonists on Human Osteochondroma Explants.
1/2020	Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells.
3/2015	The type 2 diabetes associated rs7903146 T allele within TCF7L2 is significantly under-represented in Hereditary Multiple Exostoses: insights into pathogenesis.
3/2013	Loss of β-catenin induces multifocal periosteal chondroma-like masses in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Motomi Enomoto-Iwamoto Research Topics

Disease

5	Osteochondroma (Osteocartilaginous Exostosis) 12/2021 - 03/2013
5	Osteoarthritis 01/2020 - 03/2008
4	Hypertrophy 11/2010 - 05/2005
3	Intervertebral Disc Degeneration 01/2021 - 01/2017
3	Multiple Hereditary Exostoses (Hereditary Multiple Exostoses) 06/2015 - 03/2013
2	Osteogenesis Imperfecta (Lobstein Disease) 01/2022 - 01/2019
2	Neoplasms (Cancer) 01/2020 - 01/2018
2	Heterotopic Ossification (Ectopic Ossification) 01/2020 - 04/2011
2	Exostoses 06/2015 - 09/2013
1	Hyperalgesia 01/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Chondrosarcoma 01/2020
1	Disease Progression 01/2020
1	Sclerosis 01/2018
1	Wounds and Injuries (Trauma) 01/2018
1	Inflammation (Inflammations) 01/2018
1	Tendon Injuries 01/2018
1	Back Pain (Backache) 01/2017
1	Arthralgia (Joint Pain) 12/2016
1	Type 2 Diabetes Mellitus (MODY) 03/2015
1	Hypoxia (Hypoxemia) 01/2014
1	Chondroma (Enchondroma) 03/2013
1	Myositis Ossificans (Fibrodysplasia Ossificans Progressiva) 04/2011
1	Congenital Abnormalities (Deformity) 11/2009

Drug/Important Bio-Agent (IBA)

4	CateninsIBA 12/2021 - 03/2013
3	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 12/2021 - 04/2011
3	EnzymesIBA 01/2021 - 09/2013
3	beta CateninIBA 11/2009 - 05/2005
2	Collagen Type I (Type I Collagen)IBA 01/2022 - 01/2019
2	PalovaroteneIBA 12/2021 - 01/2020
2	RetinoidsIBA 12/2021 - 11/2010
2	Retinoic Acid Receptor gammaIBA 04/2020 - 01/2020
2	Heparitin Sulfate (Heparan Sulfate)IBA 06/2015 - 09/2013
2	CollagenIBA 06/2007 - 05/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2007 - 05/2005
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2021
1	Small Leucine-Rich ProteoglycansIBA 01/2020
1	DecorinIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2018
1	heparanaseIBA 06/2015
1	Pharmaceutical PreparationsIBA 11/2014
1	kartogeninIBA 11/2014
1	Transcription Factors (Transcription Factor)IBA 01/2014
1	Proteins (Proteins, Gene)FDA Link 09/2013
1	Activin Receptors (Activin Receptor)IBA 04/2011
1	Tamoxifen FDA LinkGeneric 11/2009
1	Metalloproteases (Metalloproteinases)IBA 05/2005

Therapy/Procedure

3	Bone Plates (Bone Plate) 01/2022 - 12/2016
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019 - 01/2017
1	Drug Therapy (Chemotherapy) 01/2020
1	Therapeutics 01/2020
1	Injections 11/2009